The advent of PSA testing in the late 1980s substantially increased prostate cancer incidence rates. Concerns about overscreening and overdiagnosis subsequently led professional guidelines (circa 2000 and later) to recommend against routine PSA testing.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
We evaluated trends in prostate cancer incidence, including late-stage diagnoses, from 1995 through 2012.
We used joinpoint regression analyses to evaluate all-, localized/regional-, and distant-stage prostate cancer incidence trends based on Surveillance, Epidemiology, and End Results (SEER) data. We stratified analyses by age (50-69, 70+). We reported incidence trends as annual percent change (APC).
Overall age-adjusted incidence rates for localized/regional stage PCa have been declining since 2001, sharply from 2010 to 2012 (APC -13. 1, 95% CI -23. 5 to -1. 3). Distant-stage incidence rates have declined since 1995, with greater declines from 1995 to 1997 (APC - 8. 4, 95% CI -2. 3 to -14. 1) than from 2003 to 2012 (APC - 1. 0, 95% CI -1. 7 to -0. 4). Distant-stage incidence rates declined for men 75+ from 1995 to 2012, but increased in men 50-69 from 2004 to 2012 (APC 1. 7, 95% CI 0. 2 to 3. 2).
Guidelines discouraging routine prostate cancer screening were temporally associated with declining localized/regional prostate cancer incidence rates; however, incidence rates of distant-stage disease are now increasing in younger men.
This trend may adversely affect prostate cancer mortality rates.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2015 Dec 08 [Epub ahead of print]
Richard M Hoffman, Angela Meisner, Wadih Arap, Marc Barry, Satyan Shah, Steven Zeliadt, Charles L Wiggins
University of Iowa, University of New Mexico. , Division of Molecular Medicine, University of New Mexico Cancer Center. , Department of Pathology, UNM Health Sciences Center. , University of New Mexico. , Medicine, University of Washington. , New Mexico Cancer Center, University of New Mexico.